Correction to: Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women

Affiliations

¹ Department of Oncology Clinical Development, Radius Health, Inc., 950 Winter Street, Waltham, MA, 02451, USA. mconlan@radiuspharm.com.
² Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
³ Department of Biostatistics, Radius Health, Inc., 950 Winter Street, Waltham, MA, USA.
⁴ Department of Clinical Pharmacology, Radius Health, Inc., 950 Winter Street, Waltham, MA, USA.

Published Erratum

Maureen G Conlan et al. Eur J Drug Metab Pharmacokinet. 2020 Oct.

. 2020 Oct;45(5):691-692.

doi: 10.1007/s13318-020-00638-0.

¹ Department of Oncology Clinical Development, Radius Health, Inc., 950 Winter Street, Waltham, MA, 02451, USA. mconlan@radiuspharm.com.
² Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
³ Department of Biostatistics, Radius Health, Inc., 950 Winter Street, Waltham, MA, USA.
⁴ Department of Clinical Pharmacology, Radius Health, Inc., 950 Winter Street, Waltham, MA, USA.

Abstract

Authors would like to correct the errors in table 2.

Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women.
Conlan MG, de Vries EFJ, Glaudemans A, Wang Y, Troy S. Conlan MG, et al. Eur J Drug Metab Pharmacokinet. 2020 Oct;45(5):675-689. doi: 10.1007/s13318-020-00635-3. Eur J Drug Metab Pharmacokinet. 2020. PMID: 32661909 Free PMC article. Clinical Trial.